a New Mexico Poison and Drug Information Center , Albuquerque , NM , USA.
b Children's Hospital of Michigan Regional Poison Center , Detroit , MI , USA.
Clin Toxicol (Phila). 2018 Sep;56(9):846-851. doi: 10.1080/15563650.2018.1435887. Epub 2018 Feb 12.
BACKGROUND/OBJECTIVES: The threshold salicylate concentration commonly recommended to initiate extracorporeal elimination, in the absence of significant end-organ toxicity, is 100 mg/dL. Unfortunately, the grade of evidence to support this decision is low. Our primary aim is to describe highest reported salicylate concentrations in patients who died from acute salicylate ingestions. Our secondary aim is to determine if age or coingestants varied with highest reported salicylate concentration.
We analyzed acute salicylate fatalities reported to the National Poison Data System (NPDS) between 1 January 1986 and 31 December 2014. Included were patients who died during the index hospitalization and for which acute salicylate toxicity was the primary cause of death. We used descriptive statistics with standard deviations (SD) or 95% confidence intervals (CI) where appropriate. We created a general linear model that evaluated the association of age and coingestions with salicylate concentrations. We divided the patients into age quartiles to assess a possible interaction between age and salicylate concentration.
We identified 602 acute salicylate fatalities that fit inclusion criteria. The mean peak reported fatal salicylate concentration across all age groups was 99.19 mg/dL (± 50.2 mg/dL). The median peak fatal salicylate concentration was 97.0 mg/dL. The oldest quartile had a lower mean concentration (age >57 years; 90.4 mg/dL) than the youngest quartile (age <30 years; 111.6 mg/dL, mean difference 21.2 mg/dL, 95%CI 6.1-36.3). Fatalities with a coingestant had a lower mean concentration of 91.5 mg/dL compared to 104.8 mg/dL among those ingesting salicylates alone (mean difference 13.4 mg/dL, 95%CI 21.4-5.3). Increasing age and the presence of any coingestions were negatively associated with fatal concentrations (estimates; 95%CI 0.41; 0.61-0.021 and -14.43; 22.45-6.42, respectively). When opioids were a coingestant, mean concentration was 72.8 (mean difference 32.1 95%CI 23.1-41.1).
Using the current recommended hemodialysis threshold of 100 mg/dL, more than half of the patients would be deprived of this critical life-saving therapy. Additionally, increasing age and ingestion of other substances, especially opioids, are associated with lower peak fatal salicylate concentrations. A prospective, randomized controlled trial considering salicylate concentrations and other clinical factors may provide further guidance for hemodialysis.
背景/目的:在没有明显靶器官毒性的情况下,通常建议启动体外清除的水杨酸盐浓度阈值为 100mg/dL。遗憾的是,支持这一决策的证据等级较低。我们的主要目的是描述因急性水杨酸盐摄入而死亡的患者中报告的最高水杨酸盐浓度。我们的次要目的是确定年龄或共服药物是否与最高报告的水杨酸盐浓度相关。
我们分析了 1986 年 1 月 1 日至 2014 年 12 月 31 日期间向国家毒物数据系统(NPDS)报告的急性水杨酸盐致死病例。包括在指数住院期间死亡且急性水杨酸盐毒性为主要死因的患者。我们使用描述性统计方法,包括标准差(SD)或 95%置信区间(CI)。我们创建了一个线性回归模型,评估年龄和共服药物与水杨酸盐浓度的关系。我们将患者分为年龄四分位组,以评估年龄和水杨酸盐浓度之间可能存在的相互作用。
我们确定了 602 例符合纳入标准的急性水杨酸盐致死病例。所有年龄组报告的致命性水杨酸盐最高峰值浓度平均值为 99.19mg/dL(±50.2mg/dL)。致命性水杨酸盐最高峰值浓度中位数为 97.0mg/dL。最年长的四分位数的平均浓度较低(年龄>57 岁;90.4mg/dL),而最年轻的四分位数(年龄<30 岁;111.6mg/dL,平均差异 21.2mg/dL,95%CI 6.1-36.3)。与单独摄入水杨酸盐的患者相比,共服其他药物的患者的平均浓度较低,为 91.5mg/dL,而单独摄入水杨酸盐的患者的平均浓度为 104.8mg/dL(平均差异 13.4mg/dL,95%CI 21.4-5.3)。年龄增加和存在任何共服药物与致死性浓度呈负相关(估计值;95%CI 0.41;0.61-0.021 和-14.43;22.45-6.42)。当阿片类药物是共服药物时,平均浓度为 72.8mg/dL(平均差异 32.1mg/dL,95%CI 23.1-41.1)。
使用当前推荐的血液透析 100mg/dL 阈值,超过一半的患者将无法接受这种关键的救命治疗。此外,年龄增加和摄入其他物质,尤其是阿片类药物,与较高的致命性水杨酸盐浓度相关。一项考虑水杨酸盐浓度和其他临床因素的前瞻性、随机对照试验可能为血液透析提供进一步的指导。